已收盤 02-06 16:00:00 美东时间
+0.140
+2.88%
Longleaf Partners Small-Cap Fund (LLSCX) reported a 7.56% total return, compared with 12.81% for the Russell 2000 and 17.15% for the Russell 3000. During 2025, the fund added new positions in Shenando...
01-21 00:13
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 10:22
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Westrock Coffee业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 合并净销售额同比增长61%,主要受益于销量增长和原材料成本上涨的传导 - 饮料解决方案部门净销售额同比增长60% - 可持续采购与追溯(SS&T)部门净销售额同比增长62% **盈利能力:** - 合并调整后EBITDA达到2,320万美元,同比增长125% - 合并分部调整后EBITDA达到2,620万美元,环比增长14%,同比增长84% - 饮料解决方案部门调整后EBITDA为2,040万美元,同比增长74% - SS&T部门调整
2025-11-07 12:16
Westrock Coffee shares are trading higher after the company reported better-tha...
2025-11-07 06:01
Westrock Coffee (NASDAQ:WEST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.08) by 140.96 percent. This is a 300 percent decrease over losses of $(0.05) per share from
2025-11-07 05:24
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
2025-10-28 10:08
Telsey Advisory Group analyst Sarang Vora maintains Westrock Coffee (NASDAQ:WEST) with a Outperform and maintains $10 price target.
2025-10-27 18:42